NEUROD1
Neurogenic differentiation factor 1
Also known as: BETA2, BHF-1, bHLHa3, MODY6, NDF1_HUMAN, NEUROD
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13562
- Gene
- NEUROD1
- Ensembl
- ENSG00000162992
- Chromosome
- 2
- Canonical length
- 356 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
OverviewNCBI Gene
This gene encodes a member of the NeuroD family of basic helix-loop-helix (bHLH) transcription factors. The protein forms heterodimers with other bHLH proteins and activates transcription of genes that contain a specific DNA sequence known as the E-box. It regulates expression of the insulin gene, and mutations in this gene result in type II diabetes mellitus. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
356 residues, UniProt reviewed canonical sequence.
>Q13562|NEUROD1
1 MTKSYSESGL MGEPQPQGPP SWTDECLSSQ DEEHEADKKE DDLETMNAEE DSLRNGGEEE
61 DEDEDLEEEE EEEEEDDDQK PKRRGPKKKK MTKARLERFK LRRMKANARE RNRMHGLNAA
121 LDNLRKVVPC YSKTQKLSKI ETLRLAKNYI WALSEILRSG KSPDLVSFVQ TLCKGLSQPT
181 TNLVAGCLQL NPRTFLPEQN QDMPPHLPTA SASFPVHPYS YQSPGLPSPP YGTMDSSHVF
241 HVKPPPHAYS AALEPFFESP LTDCTSPSFD GPLSPPLSIN GNFSFKHEPS AEFEKNYAFT
301 MHYPAATLAG AQSHGSIFSG TAAPRCEIPI DNIMSFDSHS HHERVMSAQL NAIFHDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NEUROD1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.62
- Highest tissue expression
- 167 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 167 nTPM
- retina: 132 nTPM
- pancreas: 10 nTPM
- duodenum: 6.9 nTPM
- hippocampal formation: 6.1 nTPM
- stomach: 5.3 nTPM
Single-cell type
- neuroendocrine cells: 67 nCPM
- rod photoreceptor cells: 24 nCPM
- pancreatic islet cells: 6.6 nCPM
- brain excitatory neurons: 5.5 nCPM
- cone photoreceptor cells: 2.1 nCPM
- retinal bipolar cells: 1.8 nCPM
Immune cell
- basophil: 1 nTPM
- neutrophil: 0.4 nTPM
- non-classical monocyte: 0.4 nTPM
- MAIT T-cell: 0.3 nTPM
- NK-cell: 0.3 nTPM
- eosinophil: 0.2 nTPM
Brain region
- cerebellum: 150 nTPM
- hippocampal formation: 24 nTPM
- cerebral cortex: 17 nTPM
- pons: 12 nTPM
- amygdala: 6.9 nTPM
- midbrain: 5.2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about NEUROD1.
Disease | AllUniProt
Conditions NEUROD1 is implicated in, by any mechanism.
- Maturity-onset diabetes of the young 6 (MODY6) MIM:606394
- Type 2 diabetes mellitus (T2D) MIM:125853
Disease | GeneticClinVar
5 pathogenic / likely-pathogenic of 337 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Maturity-onset diabetes of the young type 6
- Type 2 diabetes mellitus
- Retinal dystrophy
- NEUROD1-related disorder
Disease | AutoantibodyPubMed
Conditions in which antibodies against NEUROD1 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for NEUROD1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
37 publications
- Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study.
2016 · J Autoimmun · RCR 4.4 · 90 citations - Immune-mediated disorders associated with idiopathic sudden sensorineural hearing loss.
2004 · Ann Otol Rhinol Laryngol · RCR 3.1 · 82 citations - The immunogloblin nature of nephritic factor (NeF).
1978 · Clin Exp Immunol · RCR 2.8 · 97 citations - Anti-Nuclear Antibodies Patterns in Patients With Systemic Lupus Erythematosus and Their Correlation With Other Diagnostic Immunological Parameters.
2022 · Front Immunol · RCR 2.4 · 24 citations - IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS.
2020 · Brain Behav Immun Health · RCR 1.7 · 26 citations
Show 20 more of 37 total
- Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage.
2001 · Br J Haematol · RCR 1.5 · 51 citations - Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.
2006 · Clin Rheumatol · RCR 1.5 · 45 citations - Hematological involvement in pediatric systemic lupus erythematosus: A multi-center study.
2021 · Lupus · RCR 1.4 · 16 citations - Antigenic analysis of the second extra-cellular loop of the human beta-adrenergic receptors.
1989 · Clin Exp Immunol · RCR 1.4 · 52 citations - Role of β2-adrenergic receptors in chronic obstructive pulmonary disease.
2021 · Life Sci · RCR 1.3 · 18 citations - Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I.
2001 · Thromb Haemost · RCR 1.2 · 44 citations - Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia.
2003 · Arq Neuropsiquiatr · RCR 0.8 · 31 citations - beta2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss.
2000 · Fertil Steril · RCR 0.8 · 23 citations - Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study.
2017 · Chin Med J (Engl) · RCR 0.8 · 17 citations - Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India.
2014 · Rheumatol Int · RCR 0.7 · 14 citations - Inhibitory and Agonistic Autoantibodies Directed Against the β2-Adrenergic Receptor in Pseudoexfoliation Syndrome and Glaucoma.
2021 · Front Neurosci · RCR 0.6 · 7 citations - beta2-adrenergic receptor gene polymorphisms in myasthenia gravis (MG).
2000 · Clin Exp Immunol · RCR 0.5 · 24 citations - Prevalence of anti-beta-2 microglobulin autoantibodies in sera of rheumatoid arthritis patients with extra-articular manifestations.
1981 · Ann Rheum Dis · RCR 0.5 · 10 citations - Alcohol dehydrogenase: an autoantibody target in patients with alcoholic liver disease.
2005 · Int J Immunopathol Pharmacol · RCR 0.4 · 14 citations - Thrombotic Primary Antiphospholipid Syndrome: the profile of antibody positivity in patients from North India.
2016 · Int J Rheum Dis · RCR 0.4 · 8 citations - Association of Serum Ferritin Levels with Hematological Manifestations in Systemic Lupus Erythematosus Patients from Western India.
2016 · J Assoc Physicians India · RCR 0.4 · 7 citations - The diagnostic challenge of acute Q fever endocarditis.
2021 · BMJ Case Rep · RCR 0.4 · 3 citations - Chorea associated with anti-phospholipid antibodies: case report.
2010 · Acta Clin Belg · RCR 0.4 · 9 citations - Autoantibodies and human immunodeficiency viruses infection: a case-control study.
2003 · Clin Exp Rheumatol · RCR 0.2 · 10 citations - Treatment of relapsing autoimmune encephalomyelitis with T cell receptor V beta-specific antibodies when proteolipid protein is the autoantigen.
1996 · J Neurosci Res · RCR 0.2 · 9 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.51
- gnomAD pLI
- 0.77
- gnomAD missense Z
- 0.23
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- amacrine cell differentiation
- anterior/posterior pattern specification
- axon development
- cell surface receptor signaling pathway via JAK-STAT
- cellular response to glucocorticoid stimulus
- cerebellum development
- dentate gyrus development
- embryonic organ morphogenesis
- endocrine pancreas development
- enteroendocrine cell differentiation
- glucose homeostasis
- inner ear development
- insulin secretion
- negative regulation of receptor signaling pathway via JAK-STAT
- negative regulation of type B pancreatic cell apoptotic process
- neurogenesis
- pancreatic A cell fate commitment
- pancreatic PP cell fate commitment
- positive regulation of apoptotic process
- positive regulation of cell differentiation
- positive regulation of DNA-binding transcription factor activity
- positive regulation of DNA-templated transcription
- positive regulation of insulin secretion
- positive regulation of neuron differentiation
- positive regulation of transcription by RNA polymerase II
- regulation of insulin secretion
- response to glucose
- sensory organ development
- signal transduction involved in regulation of gene expression
- transcription by RNA polymerase II
- regulation of intestinal epithelial structure maintenance
Molecular functions
- chromatin binding
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity
- DNA-binding transcription factor activity, RNA polymerase II-specific
- E-box binding
- protein heterodimerization activity
- RNA polymerase II-specific DNA-binding transcription factor binding
- sequence-specific double-stranded DNA binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Myc-type, basic helix-loop-helix (bHLH) domain
- Neurogenic differentiation factor NeuroD
- Neurogenic differentiation factor, domain of unknown function
- Helix-loop-helix DNA-binding domain superfamily
- Basic helix-loop-helix transcription factors
- Helix-loop-helix DNA-binding domain
- Neuronal helix-loop-helix transcription factor
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NEUROD1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NEUROD1 as an antibody target. Whether an autoantibody or antibody against NEUROD1 could matter depends on whether native NEUROD1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NEUROD1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NEUROD1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...